Search

everythinglearnresearchcommunity

for

Search:↓

Memory T cells in the skin balance staying put and moving into the blood, clustering around hair follicles, and increasing in number after infection.

HDAC4 and HDAC7 are crucial for Th17 cell development and could be targeted to treat inflammatory diseases.

IL-18 signaling helps mature Tregs move into the thymus.

The CD4 protein may play a role in the behavior of certain skin cells, affecting their growth, movement, and differentiation.

A specific type of immune cell plays a key role in causing alopecia areata and could be a target for treatment.

IL-17 plays a key role in severe hair loss in chronic alopecia areata.

Expanding regulatory T cells may help treat alopecia areata by reducing harmful immune cells.

Certain CD8+ T cells attack hair follicles in alopecia areata, suggesting they could be targeted for treatment.

Expanding CD4+ Tregs can stop hair loss in alopecia areata.

Patients with severe active alopecia areata have lower CD200 expression and an imbalance in their immune system.

NKG2D+CD4+ T cells are higher in alopecia areata patients and may be involved in the disease.

Increased Treg cells and IL-10 may help quick recovery in acute diffuse and total alopecia.

T cells affect skin cell genes in inflammatory diseases, and therapy can normalize these changes.

Increased regulatory T cell activity may lead to better outcomes in acute diffuse and total alopecia.

CD4+ skin cells may be precursors to basal cell carcinoma.

Enhancing Tregs can protect against alopecia areata.

IL-18 signaling helps mature Tregs move into the thymus.

CD8+ T cells expand significantly in alopecia areata, suggesting new treatment targets.

Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.

CD4 is crucial for maintaining skin stem cell balance and aiding wound healing.

Expanded CD8+ T cells are linked to Alopecia Areata and may cause relapse after treatment.

Tissue environment greatly affects the unique epigenetic makeup of regulatory T cells, which could impact autoimmune disease treatment.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

In alopecia areata, certain immune cells increase and express a protein linked to immune activation.

Higher levels of certain immune cells and proteins are linked to more severe lupus symptoms.

IL-17 and certain immune cells are linked to more severe alopecia areata.

CD8+ T cells are involved in alopecia areata and may cause disease relapse.